Accelovance
Accelovance
Are you from Accelovance?
  • Looking to enhance your trial's patient recruitment and retention? Accelovance's Patient Engagement Solutions is your answer. Our robust clinical call center provides clients with a full-suite of services to improve enrollment and compliance on programs of all magnitudes. Discover more https://hubs.ly/H09FPDW0
  • Scientists are taking a cue from bioluminescent marine animals to help identify which cancer immunotherapies are working. CAR-T cells are a promising area in cancer research, but thus far the method for determining effectiveness (the radioactive chorimium release assay) has been costly and complex. A new assay, using the animal luciferases enzyme found in deep sea crustaceans and shrimp, is proving to be powerful, inexpensive and fast at detecting cancer cell death. This is an exciting discovery for cancer immunotherapy. Read more https://hubs.ly/H09FSRH0
  • Do you have a promising immuo-oncology therapy in development? Turn to Accelovance for results. Accelovance specializes in oncology clinical development, with a strong focus in IO programs including immune checkpoint modulators, cellular immunotherapies, oncolytic viruses, peptide vaccines, bispecific T-cell engagers, and tumor vaccines. Set up a meeting with our of our medical experts and learn more. https://hubs.ly/H09y1110
  • Accelovance is pleased to be kicking off a new trial for bladder cancer. Our early phase oncology team is ready to take on this program. Learn more about our HERO Initiative, helping early research in oncology. https://hubs.ly/H09x_pw0

Looking to enhance your trial's patient recruitment and retention? Accelovance's Patient Engagement Solutions is your answer. Our robust clinical call center provides clients with a full-suite of services to improve enrollment and compliance on programs of all magnitudes. Discover more https://hubs.ly/H09FPDW0

Scientists are taking a cue from bioluminescent marine animals to help identify which cancer immunotherapies are working. CAR-T cells are a promising area in cancer research, but thus far the method for determining effectiveness (the radioactive chorimium release assay) has been costly and complex. A new assay, using the animal luciferases enzyme found in deep sea crustaceans and shrimp, is proving to be powerful, inexpensive and fast at detecting cancer cell death. This is an exciting discovery for cancer immunotherapy. Read more https://hubs.ly/H09FSRH0

Do you have a promising immuo-oncology therapy in development? Turn to Accelovance for results. Accelovance specializes in oncology clinical development, with a strong focus in IO programs including immune checkpoint modulators, cellular immunotherapies, oncolytic viruses, peptide vaccines, bispecific T-cell engagers, and tumor vaccines. Set up a meeting with our of our medical experts and learn more. https://hubs.ly/H09y1110

Accelovance is pleased to be kicking off a new trial for bladder cancer. Our early phase oncology team is ready to take on this program. Learn more about our HERO Initiative, helping early research in oncology. https://hubs.ly/H09x_pw0

Jobs at at Accelovance

There are no jobs at the current time